// App-Quantinova.ai

9028 : Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR).

Researchers

Presenter

  • David A. Smith

Principal Investigators

  • Johan F. Vansteenkiste

  • Louis Fehrenbacher

  • Keunchil Park

  • Julien Mazieres

  • Achim Rittmeyer

  • Angel Artal-Cortes

  • Conrad R. Lewanski

  • Fadi S. Braiteh

  • Jing Yi

  • Pei He

  • Wei Zou

  • Marcin Kowanetz

  • Daniel Waterkamp

  • Marcus Ballinger

  • Daniel S. Chen

  • Alan Sandler

  • Alexander I. Spira

Medical Centers

  • Compass Oncology, Vancouver, WA

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • NSABP/NRG Oncology, and Kaiser Permanente Northern California, Novato, CA

  • Hopital Larrey Centre Hospitalier Universitaire Toulouse, Toulouse, France

  • Lungenfachklinik Immenhausen, Kassal, Germany

  • H. Universitario Miguel Servet, Zaragoza, Spain

  • Charing Cross Hospital, London, United Kingdom

  • The US Oncology Network/McKesson Specialty Health, The Woodlands, TX

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Virginia Cancer Specialists Research Institute, and Oncology Research, Fairfax, VA

Locations

  • Germany

  • Spain

  • United Kingdom

  • Switzerland

  • United States

  • France

  • Belgium

Companies

  • Genentech, Inc.

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

  • Docetaxel

Outcome

  • Positive

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01903993

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved